Clinical trials are obviously important.  The results influence what drugs are approved by regulatory bodies, which can have a billion-dollar impact on companies. Clinical trials have always…

New cells develop in the heart but how these cardiac cells are born and how frequently they are generated remains unclear. New research from Brigham and Women's Hospital used a novel method to…

DUJazz Pharmaceuticals announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an…

Cardio3 BioSciences (C3BS) announced it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic…

Autologous stem cells from bone marrow 3 or 7 days following a heart attack did not improve heart function six months later, according to a new clinical trial.  The results of this TIME (…

Medivir AB has announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's…

Keryx Biopharmaceuticals, Inc. has announced the initiation of a Phase 2 study of Zerenex (ferric citrate), an ferric iron-based phosphate binder drug candidate, in managing serum phosphorus and iron…

Glybera is the first gene therapy approved by regulatory authorities in the Western world. niQure announced it has received approval from the European Commission for the gene therapy Glybera(R) (…

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for its treatment and prevention of bacterial vaginosis (BV) with a proven cure rate of 80 percent…

Abbott today announced results from a post-hoc sub-analysis of the 52-week HUMIRA® (adalimumab) ULTRA 2 study. Results of the analysis showed clinically meaningful rates of mucosal healing at week…